NEW YORK (GenomeWeb) – HTG Molecular Diagnostics said today that it has entered into a third project for a new clinical assay development program under an existing master assay development, commercialization, and manufacturing agreement with Qiagen.

The new project relates to development activities for a next-generation sequencing-based clinical trial assay associated with a sponsored project agreement between Qiagen and an undisclosed pharmaceutical company, according to a document filed by HTG with the US Securities and Exchange Commission.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a 360Dx or GenomeWeb account?
Login Now.